Yung-Tsi Bolon

Dr. Yung-Tsi Bolon

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RPRachel Phelan
Rachel Phelan
MCMin Chen
Min Chen
CBCaitrin Bupp
Caitrin Bupp
YBYung-Tsi Bolon
Yung-Tsi Bolon
LBLarisa Broglie
Larisa Broglie
MAMukta Arora
Mukta Arora
Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, and treatment modalities evolve, documenting HCT trends and outcomes is critical. This report from the Center for International Blood and Marrow Transplant Research (CIBMTR) provides an update on current transplantation activity and survival rates in the United States. Additional data on the use and outcomes of HCT in the adolescent and young adult (AYA) population are included. AYA patients more frequently receive peripheral blood stem cell grafts than pediatric patients, which may reflect differences in practice in pediatric versus adult treatment centers. The proportions of donor types also differ those in adult and pediatric populations. Outcomes for patients in the AYA age range are similar to those of pediatric patients for acute myelogenous leukemia but worse for acute lymphoblastic leukemia. Outcomes for both leukemias are better in AYA patients compared with older adults. Comparing the time periods 2000 to 2009 and 2010 to 2019 revealed significant improvement in overall survival across the age spectrum, but the greatest improvement in the AYA age group.

15 March 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JAJeffery J. Auletta
Jeffery J. Auletta
JKJianqun Kou
Jianqun Kou
MCMin Chen
Min Chen
YBYung-Tsi Bolon
Yung-Tsi Bolon
LBLarisa Broglie
Larisa Broglie
BSBronwen E. Shaw
Bronwen E. Shaw
The use of HLA-mismatched donors could enable more patients with ethnically diverse backgrounds to receive allogeneic hematopoietic cell transplantation (HCT) in the United States. However, real-world trends and outcomes following mismatched donor HCT for diverse patients remain largely undefined. We conducted this study to determine whether the use of mismatched donor platforms have increased the access to allogeneic HCT for ethnically diverse patients, particularly through the application of novel graft-versus-host disease (GVHD) prophylaxis regimens, and whether outcomes for diverse patients are comparable to those of non-Hispanic White patients. This observational cross-sectional study used real-world data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. All patients receiving their first allogeneic HCT in the United States between 2009 and 2020 were included, with a focus on transplantations performed in 2020. Data from patients undergoing allogeneic HCT using bone marrow, peripheral blood, or cord blood from HLA-matched or mismatched related and unrelated donors were analyzed. Specifically, relative proportion of allogeneic HCT was generated as percentage of total for donor type and for patient age, disease indication, GVHD prophylaxis, and race and ethnicity. Causes of death were summarized using frequencies, and the Kaplan-Meier estimator was used for estimating overall survival. Compared to matched related donor and matched unrelated donor HCT, more ethnically diverse patients received mismatched unrelated donor, haploidentical donor, and cord blood HCT. Although matched unrelated donor remains the most common donor type, the use of haploidentical donors has increased significantly over the last 5 years. Paralleling this increase in haploidentical HCT is the increased use of post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis. Relative to previous transplantation eras, the most contemporary era is associated with the highest survival rates following allogeneic HCT irrespective of patient race and ethnicity. Nonetheless, disease relapse remains the primary cause of death for both adult and pediatric allogeneic HCT recipients by donor type and across all patient racial/ethnic groups. Ethnically diverse patients are undergoing allogeneic HCT at higher rates, largely through the use of alternative donor platforms incorporating PTCy. Maintaining access to potential life-saving allogeneic HCT using alternative donors and novel GVHD prophylaxis strategies and improving HCT outcomes, particularly disease relapse, remain urgent clinical needs.

5 July 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
AJAntonio M. Jimenez Jimenez
Antonio M. Jimenez Jimenez
SSStephen R. Spellman
Stephen R. Spellman
IPIoannis Politikos
Ioannis Politikos
SMShannon R. McCurdy
Shannon R. McCurdy
SDSteven M. Devine
Steven M. Devine
BSBrian C. Shaffer
Brian C. Shaffer
Allogeneic hematopoietic cell transplantation (HCT) remains a curative therapy for many patients with hematologic malignancies, bone marrow failure syndromes, inborn errors of immunity and metabolic disorders. Current donor selection strategies typically prioritize the selection of an HLA-matched donor over HLA mismatched ("alternative") donor sources, with a hierarchical approach to the donor search. More recent data challenge this rubric, particularly in the context of novel graft versus host disease (GVHD) prophylaxis strategies that demonstrate improved outcomes in alternative donor HCT recipients. In this setting, an increased emphasis on non-HLA factors (both donor characteristics and systemic factors) in determining donor selection is now feasible. In this guideline, we review recent evidence from prospective clinical trials as well as high-quality observational studies and provide expert panel recommendations on donor selection algorithms and prioritization in the era of novel GVHD prophylaxis. We then highlight important questions still to be answered in our field.

1 May 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PCPietro Crivello
Pietro Crivello
EAEsteban Arrieta-Bolaños
Esteban Arrieta-Bolaños
MHMeilun He
Meilun He
TWTao Wang
Tao Wang
SFStephanie Fingerson
Stephanie Fingerson
KFKatharina Fleischhauer
Katharina Fleischhauer
PURPOSE: Immunopeptidome divergence between mismatched HLA-DP is a determinant of T-cell alloreactivity and clinical tolerability after fully HLA-A, -B, -C, -DRB1, -DQB1 matched unrelated donor hematopoietic cell transplantation (UD-HCT). Here, we tested this concept in HLA-A, -B, and -C disparities after single class I HLA-mismatched UD-HCT. PATIENTS AND METHODS: We studied 2,391 single class I HLA-mismatched and 14,426 fully HLA-matched UD-HCT performed between 2008 and 2018 for acute leukemia or myelodysplastic syndromes. Hierarchical clustering of experimentally determined peptide-binding motifs (PBM) was used as a proxy for immunopeptidome divergence of HLA-A, -B, or -C disparities, allowing us to classify 1,629/2,391 (68.1%) of the HLA-mismatched UD-HCT as PBM-matched or PBM-mismatched. Risks associated with PBM-matching status were assessed by Cox proportional hazards models, with overall survival (OS) as the primary end point. RESULTS: Relative to full matches, bidirectional or unidirectional PBM mismatches in graft-versus-host (GVH) direction (PBM-GVH mismatches, 60.7%) were associated with significantly lower OS (hazard ratio [HR], 1.48; P < .0001), while unidirectional PBM mismatches in host-versus-graft direction or PBM matches (PBM-GVH matches, 39.3%) were not (HR, 1.13; P = .1017). PBM-GVH mismatches also had significantly lower OS than PBM-GVH matches in direct comparison (HR, 1.32; P = .0036). The hazards for transplant-related mortality and acute and chronic graft-versus-host disease but not relapse increased stepwise from full HLA matches to single PBM-GVH matches, and single PBM-GVH mismatches. A webtool for PBM-matching of single class I HLA-mismatched donor-recipient pairs was developed. CONCLUSION: PBM-GVH mismatches inform mortality risks after single class I HLA-mismatched UD-HCT, suggesting that prospective consideration of directional PBM-matching status might improve outcome. These findings highlight immunopeptidome divergence between mismatched HLA as a driver of clinical tolerability in UD-HCT.

11 August 2022 in Blood
Verified
Journal Article
Open access
PDF file
EAEsteban Arrieta-Bolaños
Esteban Arrieta-Bolaños
PCPietro Crivello
Pietro Crivello
MHMeilun He
Meilun He
TWTao Wang
Tao Wang
SGShahinaz Gadalla
Shahinaz Gadalla
KFKatharina Fleischhauer
Katharina Fleischhauer

14 August 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ACAbu Sayed Chowdhury
Abu Sayed Chowdhury
MMMartin Maiers
Martin Maiers
SSStephen R. Spellman
Stephen R. Spellman
TDTushar Deshpande
Tushar Deshpande
YBYung-Tsi Bolon
Yung-Tsi Bolon
SDSteven Michael Devine
Steven Michael Devine
When patients do not have matched siblings or well-matched unrelated donors (MUD), hematopoietic cell transplantation (HCT) can still be successful using an HLA-mismatched unrelated donor (MMUD), in combination with post-transplant cyclophosphamide (PTCy), abatacept, or other novel approaches. This may allow clinicians to choose a suitable donor from a wide range of donor options while optimizing other donor selection characteristics, including donor age. We hypothesized that allowing for 5/8 HLA match level considering high resolution matching at HLA-A, -B, -C and -DRB1, there is potential to close the donor availability gap for all patients regardless of their race/ethnicity. In this work, we estimate the likelihood of matching for all race/ethnic groups at different HLA match thresholds. Our study aimed to assess the potential for identifying an available MUD or MMUD in the National Marrow Donor Program® (NMDP)/Be The Match® (BTM) donor registry for 21 detailed and 5 broad racial/ethnic groups, utilizing high-resolution HLA matching for HLA-A, B, C, and DRB1 at various levels (8/8, 7/8, 6/8, and 5/8). We used donor registry population data from the NMDP/BTM in 2020 and redistributed the donor registry data according to existing population ratios, accounting for demonstrated donor availability. Finally, we utilized a genetic model at the population level to estimate the match likelihood for detailed and broad racial/ethnic groups. 8/8 HLA match likelihoods ranging from 16-74% were obtained for various detailed race/ethnic groups with available donors ≤35 years old. When considering more mismatches within the HLA loci, registry coverage became >99% with a 5/8 HLA match level for donors of all ages or those ≤ 35 years old, with DPB1 T cell epitope permissive matching, or when searching donors outside of their race/ethnic group. Our registry models demonstrate the potential of using MMUDs at various HLA match levels to study whether this will expand access to HCT across race/ethnic groups. Furthermore, expanded donor options may erase the donor availability gap for all patients while allowing for selection of MMUDs with favorable characteristics such as younger age.